What factors drove the changes in SLR Investment's revenue and profit?

What were the key takeaways from SLR Investment’s earnings call?

What is the revenue and EPS growth rate for SLR Investment year over year?

What is SLR Investment's latest dividend and current dividend yield?

What does SLR Investment do and what are its main business segments?

What were the key takeaways from SLR Investment's earnings call?

What is SLR Investment's gross profit margin?

Did SLR Investment beat or miss consensus estimates last quarter?

- **Portfolio Growth and Stability**: 17.1% annualized portfolio growth since 2020, with 83% of Q3 originations in specialty finance. ABL portfolio at $1.4 billion (44% of assets) with 13.4% yield.
- **Credit Quality Leadership**: 94.8% first lien loans, 99.5% performing assets, outperforming peer BDCs. Avoided high-risk cash flow lending (15.3% of portfolio).
- **Liquidity and Debt Management**: $850 million deployable capital, 1.13x net debt-to-equity ratio. Issued $125M unsecured notes at 5.95%-5.96%.
- **Dividend Sustainability**: NAV growth offset $0.01 dividend shortfall. Leverage capacity (1.13x to 1.25x) provides buffer against rate cuts.
- **Strategic Expansion**: 100+ hires in ABL/equipment finance, including JPMorgan veteran. Life sciences pipeline triple 2024 levels, focusing on late-stage assets.


**【CEO Summary Section】**
- **Portfolio Stability and Growth**: Reported net investment income of $0.40 per share, with a 9.4% annualized return on equity. Comprehensive portfolio grew at a 17.1% annualized rate since 2020, driven by specialty finance strategies.
- **Strategic Shift to ABL**: 83% of third-quarter originations in specialty finance, with ABL portfolio totaling $1.4 billion (44% of total assets). Focused on direct lending with rigorous collateral monitoring.
- **Market Differentiation**: Portfolio credit quality metrics (94.8% first lien loans, 99.5% performing assets) outperform peer BDCs. Avoided high-risk cash flow lending, with only 15.3% of portfolio in sponsor-backed loans.

**【CFO Financial Commentary】**
- **Financial Performance**: Net asset value of $18.21 per share (flat year-over-year). Third-quarter net investment income of $21.6 million ($0.40 per share), matching base dividend. Liquidity of $850 million available for deployment.
- **Debt Management**: Issued $125 million in unsecured notes at 5.95%-5.96%, maintaining investment-grade ratings. Net debt-to-equity ratio of 1.13x, with no near-term refinancing obligations.
- **Portfolio Yield**: Weighted average yield of 12.2%, stable quarter-over-quarter. ABL portfolio yield of 13.4%, offsetting lower cash flow yields (10.2%).

**【Q&A Highlights】**
- **ABL Market Dynamics**: Emphasized infrastructure barriers to entry, with 100+ hires in ABL and equipment finance. Recent ABL originations up 12.7% year-over-year, driven by corporate liquidity needs.
- **Dividend Sustainability**: Despite SOFR sensitivity (7 cents NOI impact per 100bp rate cut), NAV growth offset dividend shortfall. Leverage capacity (1.13x to 1.25x) provides buffer for rate headwinds.
- **Life Sciences Pipeline**: Expanded to triple 2024 levels, focusing on late-stage assets with commercialization milestones. 88% of portfolio companies have >12 months of cash runway.
- **Regulatory Response**: Rejected high-risk ABL investments (e.g., First Brands) due to red flags, highlighting SLR's underwriting discipline.

**【Strategic Initiatives】**
- **Team Expansion**: 100+ hires over two years, including Max Fowell (JPMorgan ABL veteran), to strengthen ABL capabilities. Acquired Webster Bank's factoring business to expand specialty finance.
- **Portfolio Resilience**: 93% of third-quarter originations in specialty finance, with 99.5% of portfolio on cost basis performing. Minimal PIC income (de minimis), reducing earnings volatility.


SLR Investment Corp. (SLRC) Q3 2025 Earnings Call Transcript

- **Record originations**: $567M Q2, with 83% of portfolio now in specialty finance.
- **ABL dominance**: $373M ABL originations, targeting complex borrowers with unpledged assets.
- **Credit strength**: 99.5% performing debt, 0.2% PIK income, and 1.17x net leverage.
- **Dividend coverage**: Full quarter deployment of new originations would cover $0.41 dividend.
- **Economic resilience**: 98% portfolio in non-cyclical sectors, with ABL stress limited to cyclical borrowers.

**【Management Opening Remarks】**
- Q2 2025 net investment income: $0.40 per share (flat quarter-over-quarter), with net income of $0.44 per share.
- NAV per share: $18.19 (flat year-over-year), with annualized net income return of 10%.
- Record originations of $567M (vs. $387M repayments), driven by ABL growth and strategic portfolio shift to specialty finance.
- 83% of portfolio now in specialty finance, with 96% of Q2 originations in asset-based lending.

**【CEO Commentary】**
- ABL originations reached $373M (highest in SLR history), targeting complex borrowers with unpledged assets (e.g., agricultural suppliers, jewelry retailers).
- Portfolio credit quality metrics: 99.5% performing debt, 95.9% first lien senior secured loans, and 0.2% PIK income.
- Specialty finance strategies provide downside protection via collateral (e.g., receivables, inventory) and dynamic borrowing base frameworks.
- Equipment finance portfolio shrunk by 10% to $1B, with focus on investment-grade corporate lessees.
- Life sciences portfolio at $215M, with 75% of companies having >12 months of cash runway.
- Sponsor finance portfolio reduced to $550M (16.9% of total), focused on non-cyclical sectors like healthcare.

**【CFO Financial Commentary】**
- GAAP net income: $21.6M ($0.40 per share), with $2.6M net realized/unrealized gains.
- Debt metrics: $1.2B total debt, 1.17x net debt-to-equity ratio, and $650M deployable capital.
- Unsecured debt issuance: $50M at 5.96% (July 2025), with no near-term maturities until December 2026.
- Q3 2025 base dividend: $0.41 per share (payable September 26).

**【Q&A Highlights】**
- New originations yield: 11.8% (vs. 10% for exits), with full quarter deployment expected to cover dividend.
- ABL pipeline remains robust, with no new entrants due to infrastructure barriers.
- Equipment finance fair value decline driven by portfolio shrinkage, with plans to rebuild through investment-grade leases.
- SSLP performance: $1.1M Q2 income (9.3% annualized yield), with $70M deployment capacity.
- Economic resilience: 98% portfolio in non-cyclical sectors, with ABL stress limited to cyclical borrowers.

SLR Investment Corp. (SLRC) Q2 2025 Earnings Call Transcript

- **Q1 Resilience**: $0.41 per share NII maintained despite rate lag, 12.2% portfolio yield.
- **Strategic Shift**: 80% specialty finance, $361M originations (38% YoY), <1% tariff exposure.
- **ABL Growth**: 13.8% yield, 254 borrowers, capitalizing on regional bank exit.
- **Equipment Finance Edge**: 11.5% yield, lease extensions mitigate tariff costs.
- **Life Sciences Stability**: 89% of portfolio with >12 months cash runway, 12.5% yield.
- **Pipeline Momentum**: 75-80% ABL focus, $800M deployment capacity.


**【CEO Opening Remarks】**
- Q1 2025 net investment income of $0.41 per share, matching the base dividend, despite a 100bps FOMC rate cut lag effect.
- 80% of portfolio now in specialty finance, with $361M originations (38% YoY growth) and 12.2% portfolio yield.
- Shift to asset-based lending (ABL) and equipment finance to mitigate tariff risks, with <1% portfolio exposure to tariffs.

**【CFO Financial Highlights】**
- NAV of $18.16 per share (-$0.04 QoQ), with $990.5M total assets and $1B debt outstanding (1.04x net debt/eq).
- Q1 gross investment income $53.2M, net expenses $31.1M, resulting in $0.41 per share NII.
- Unsecured debt at 6.14% (190bps over 3-year Treasury), with no near-term maturities until 2026.

**【Bruce Spohler: Portfolio Update】**
- **ABL Segment**: $164M new originations, 13.8% yield, 254 borrowers, leveraging regional bank retrenchment.
- **Equipment Finance**: $128M originations, 11.5% yield, 636 borrowers, benefiting from tariff-driven lease extensions.
- **Life Sciences**: $25M new investments, 12.5% yield, 89% of portfolio with >12 months cash runway.
- **SSLP**: $1.9M income (15.7% yield), $70M deployment capacity.

**【Q&A Key Takeaways】**
- **Pipeline Mix**: 75-80% weighted towards ABL, with 38% YoY origination growth.
- **Tariff Impact**: <1% portfolio exposure, ABL collateralized by liquid assets with real-time monitoring.
- **Equipment Finance Upside**: Lease extensions and asset sales drove Q1 onetime gains, potential for elevated income.
- **Cash Flow Lending**: Focused on short-duration, sponsor-backed add-ons with mid-single-digit EBITDA growth.


SLR Investment (SLRC)-8 May 25-2025 Q1 Earnings call transcript

- **15-Year Milestone Achievement**: $7.5B+ investments with <11 basis points loss rate, showcasing disciplined underwriting.
- **Specialty Finance Dominance**: 79% portfolio in ABL, equipment, and life sciences, driving 12.1% portfolio yield.
- **Stable NAV & Dividend Coverage**: $18.20 NAV (flat QoQ), 95% NII coverage with $0.41 dividend.
- **ABL Growth Catalyst**: 14.6% yield, 79% Q4 originations in specialty finance, supported by Webster Bank platform.
- **Equipment Finance Resilience**: 10.7% yield with inflation-driven lease extensions, stable asset/liability matching.
- **Life Sciences De-Risking**: 87%+ companies with >12 months cash runway, 12% portfolio yield.
- **Sponsor Finance Caution**: 10.6% yield vs. 400+bps spreads; selective deployment as M&A activity may recover in 2025.


**【CEO Opening Remarks】**
- Celebrated 15-year anniversary since IPO, with $7.5B+ investments and <11 basis points loss rate.
- Emphasized multi-strategy approach, with 79% portfolio allocation to specialty finance (ABL, equipment, life sciences).
- Q4 NII per share flat YoY at $0.44, covering $0.41 dividend; full-year NII up 5% YoY to $1.77.
- Portfolio yield improved to 12.1% (Q3: 11.8%), with 96.4% in first lien loans and only 0.6% on non-accrual.

**【CFO Financial Highlights】**
- NAV stable at $18.20 per share (Q3: $18.20), up 0.6% YoY.
- Q4 gross investment income $55.6M vs. $59.8M prior quarter; expenses down 10% to $31.8M, driving 95% NII coverage.
- Issued $50M unsecured notes at 6.14%, reducing debt-to-equity to 1.03x (target 0.9x-1.25x).
- $900M+ deployment capacity across SSLP and specialty finance.

**【Bruce Spohler: Portfolio Breakdown】**
1. **Sponsor Finance (20% of portfolio):** Yield 10.6% (Q3: 11.1%), focus on recession-resistant sectors (healthcare, BFS). Q4 originations $20M vs. repayments $100M.
2. **ABL (32% of portfolio):** Yield 14.6%, 79% Q4 originations in specialty finance. Acquired Webster Bank ABL platform, with $128M new originations.
3. **Equipment Finance (37% of portfolio):** Yield 10.7% (Q3: 9.4%), benefiting from fixed-rate assets and inflation-driven lease extensions.
4. **Life Sciences (8% of portfolio):** 87%+ companies with >12 months cash runway; Q4 originations $6M, yield 12%.

**【Q&A Key Takeaways】**
- **Acquisition Strategy:** Passed on 2+ portfolio acquisitions in 2024 due to credit underwriting concerns; focused on organic ABL growth.
- **Sponsor Finance Outlook:** Spread compression (400bps+) and term loosening limit returns; expect stability in 2025 as M&A activity may rebound.
- **ABL Pipeline:** $338M Q4 originations vs. $442M repayments; 94% Q4 originations in specialty finance, driven by regional bank exits.
- **Equipment Finance Resilience:** Floating-rate debt matched with fixed-rate assets; 4-year average loan duration limits repayment volatility.
- **Life Sciences Recovery:** Early signs of pipeline improvement; regulatory environment managed by 20+ years of sector expertise.


SLRC

SLRC fundamentals

Earnings Call

You can ask Aime